Kinetic Concepts, Inc. (KCI) announced it has completed its acquisition of Systagenix, an established provider of advanced wound care products based in the United Kingdom. The acquisition of Systagenix enhances KCI’s position as a leading provider of transformational healing solutions with a diverse product portfolio dedicated to advancing the practice of medicine and improving patient lives around the world. The purchase price was $485 million.

Goldman, Sachs & Co. (lead advisor), BofA Merrill Lynch and Morgan Stanley provided financial advice to KCI. Debt financing for the transaction was provided by BofA Merrill Lynch, Morgan Stanley and Goldman, Sachs & Co. Simpson Thacher & Bartlett LLP and Kirkland & Ellis LLP acted as legal advisors to KCI. Jones Day acted as legal advisor to Systagenix.

As previously announced, KCI, Systagenix and LifeCell Corporation now form one company, a global leader in medical technology with more than $2 billion in revenue, poised for future success as a geographically diversified company with world-class wound care and biologics franchises.

KCI is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world.

LifeCell, based in Bridgewater, NJ, is a leader in regenerative medicine, develops and markets innovative tissue repair products for the reconstructive, orthopedic and urogynecologic biosurgery markets.